Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HBM Holdings Ltd. ( (HK:2142) ) has provided an announcement.
HBM Holdings Ltd. has entered into a global strategic collaboration and license agreement with Bristol Myers Squibb to develop next-generation multi-specific antibodies. This partnership could bring Harbour BioMed up to $1.125 billion in payments and royalties, potentially enhancing its market position and offering significant opportunities for growth.
The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
More about HBM Holdings Ltd.
HBM Holdings Ltd., also known as Harbour BioMed, operates in the biopharmaceutical industry, focusing on the discovery and development of innovative therapeutics, particularly multi-specific antibodies.
Average Trading Volume: 5,594,161
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.87B
Find detailed analytics on 2142 stock on TipRanks’ Stock Analysis page.